Coloplast’s New Catheter Coating Study: A Potential Game-Changer for Patient Comfort

Coloplast A/S ((GB:0QBO)) announced an update on their ongoing clinical study.

Coloplast A/S recently completed a clinical study titled Clinical Investigation of a New Coating for Urinary Intermittent Catheters in Healthy Volunteers. The study aimed to confirm that a newly developed hydrophilic coating for male intermittent catheters is non-inferior to the existing comparator in terms of overall discomfort during catheterization. This research is significant as it could enhance patient comfort and broaden Coloplast’s product offerings.

The study tested two devices: the SpeediCath® Standard male catheter with a new coating and the existing SpeediCath® Standard male catheter. Both are designed for intermittent catheterization to drain the bladder, with the new coating intended to improve user comfort.

This was a double-blinded, randomized, crossover study involving 32 healthy male volunteers. Participants were catheterized in a hospital setting by healthcare professionals using both devices in a randomized order. The primary purpose was treatment, and the study employed a double-masking approach to ensure unbiased results.

The study commenced on May 6, 2025, and its primary completion was in August 2025, with the last update submitted on August 11, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which can influence the timing of product launches and investor decisions.

The successful completion of this study could positively impact Coloplast’s stock performance by potentially expanding its market share in the catheter industry. Investors might view this as a strategic move to enhance the company’s competitive edge against other players in the medical device sector.

The study is now completed, and further details are available on the ClinicalTrials portal.